 |
INTRODUCTION |
Since the identification of dystrophin, the product of the
Duchenne muscular dystrophy gene at Xp21, molecular genetics has moved
quickly (1, 2). The deficiency of dystrophin in Duchenne muscular
dystrophy (DMD)1 and its first animal
model, the mdx mouse, leads to
a dramatic reduction in a group of previously unknown proteins
identified as the dystrophin-associated protein complex.
In the last few years, the dystrophin-associated protein complex
proteins have been isolated; their genes have been cloned; and the
following model of the complex has been hypothesized (3-5). Dystrophin
is a large rod-shaped protein, primarily localized beneath the muscle
cell membrane. Its actinin-like N terminus binds F-actin (6), whereas
its C terminus is anchored to the transmembrane protein,
-dystroglycan, which is linked through
-dystroglycan to the
extracellular merosin (laminin-2) (7). Then, this complex bridges the
muscle membrane from the cytoskeleton to the extracellular matrix. In
addition, dystroglycan is the receptor for agrin, a protein with a
pivotal role in the clustering of acetylcholine receptors at the
neuromuscular junction (8-10) and a fundamental element of the basal
lamina (11). At the muscle membrane, this complex is associated with
the hydrophobic sarcospan DAP25
(dystrophin-associated protein; A5)
(12) and the sarcoglycan complex, which is composed of at least four
interacting transmembrane glycoproteins:
-sarcoglycan (DAG50
(dystrophin-associated
glycoprotein), A2, adhalin) (13, 14),
-sarcoglycan
(DAG43, A3b) (15, 16),
-sarcoglycan (DAG35, A4) (17), and
-sarcoglycan (18). Mutations in the laminin-
2 gene are
responsible for congenital muscular dystrophy (19); mutations in the
-,
-,
-, and
-sarcoglycan genes cause limb-girdle muscular
dystrophies 2C, 2D, 2E, and 2F (13, 15-17, 20, 21), respectively; and
mutations in the caveolin-3 gene cause a form of autosomal dominant
limb-girdle muscular dystrophy (22, 23). In addition, animal models
have been identified (24) or created by homologous recombination to
establish the role of each component of the dystrophin-associated
protein complex (25-28).
The extreme C terminus of dystrophin, which lies beneath the muscle
membrane, is associated directly with a group of cytoplasmic peripheral
membrane proteins known as syntrophins (29-34). A similar interaction
has been demonstrated with utrophin, the autosomally encoded
dystrophin-related protein (35), and with some dystrobrevin isoforms
(36-38). The three known syntrophin isoforms,
1,
1, and
2,
are encoded by distinct genes with specific expression (33).
1-Syntrophin is most abundant in skeletal muscle, where it is
located close to the sarcolemma together with
1-syntrophin. In
contrast,
2-syntrophin is largely concentrated at the neuromuscular junction, but is barely detectable at the sarcolemma. Syntrophins bind
directly to the C-terminal domain of dystrophin, in the region encoded
by exons 74 and 75 (34, 39-41). This region is contained in almost all
mini-dystrophin transcripts starting from alternative distal promoters
(42, 43). These shorter dystrophins, called apodystrophins or Dp, have
nearly ubiquitous expression. Similar binding has been
ascertained for a homologous region in utrophin and
- and
-dystrobrevins (36, 38, 44, 45). In DMD, the sarcolemmal syntrophins
are lost, whereas
2-syntrophin remains localized at the
neuromuscular junction.
Each syntrophin has a characteristic domain organization in mammals
(human, mouse, rabbit) as well as in the genetically distant Torpedo californica. Two pleckstrin homology (PH) domains
and one PDZ domain are constantly present (46, 47), with the first PH
domain split into two regions (PH1a and PH1b) by the PDZ domain and its
flanking regions. In addition, another region has been recognized in
the C-terminal 57 amino acids and termed the syntrophin unique (SU)
domain (32, 33). There are indications that this domain may be directly
involved in dystrophin binding. Here, we report the identification,
through expressed sequence tag (EST) data base searching and cDNA
library screening, of two novel human genes belonging to the syntrophin family.
 |
EXPERIMENTAL PROCEDURES |
Isolation of Human
1- and
2-Syntrophin
cDNAs--
Approximately 500,000 plaques from a human fetal brain
cDNA library in the
gt10 vector (CLONTECH)
and the NT2 neuronal precursor cell cDNA library in the Uni-ZAP XR
vector (Stratagene) were screened using EST clones 49263 and c-1gb01
(IMAGE Consortium) according to standard procedures (48). Sixteen
positive clones (eight for each probe) were isolated. The open reading
frames of
1- and
2-syntrophins were sequenced in at least two
independent clones.
Northern Blotting--
Human total RNA and rat poly(A) RNA
Northern blots were purchased from CLONTECH and
Origene, respectively, and hybridized according to standard procedures
(48). The 701- and 432-bp rat cDNA fragments, used as probes for
1- and
2-syntrophins, were obtained by RT-PCR using
human-specific primer pairs.
PCR Conditions--
All PCR amplifications were performed in a
PTC-100 thermal cycler (MJ Research, Inc.) as described previously
(18).
Computational Analysis--
Multiple sequence alignment of
proteins was realized using the CLUSTAL W1.7 program with default
parameters (49). The alignment data were also utilized to obtain a
phylogenetic tree of proteins. A prevision of secondary structure was
obtained using the PHDsec algorithm (50). To search domains or
functional sites in the sequences, we scanned PROFILE and PROSITE data
bases using the ISREC web site.
Induction and Purification of Fusion Proteins--
The cDNAs
encoding
1-syntrophin (amino acids 195-302) and
2-syntrophin
(amino acids 209-299) as well as the corresponding regions of
1-syntrophin (amino acids 173-505),
1-syntrophin (amino acids
205-351), and
2-syntrophin (amino acids 193-357) were cloned in
frame with GST into the pGEX-2TK vector (Amersham Pharmacia Biotech),
introduced into Escherichia coli JM109 cells, and induced
using standard procedures.
The GST fusion proteins used in rabbit polyclonal antibody production
(GST-
1-syntrophin and GST-
2-syntrophin) were purified using a
continuous elution SDS-polyacrylamide gel electrophoresis apparatus
(Model 491 Prep Cell, Bio-Rad), digested with thrombin protease
(Amersham Pharmacia Biotech), and reloaded on the apparatus to separate
GST from peptide. Protein concentration was determined (Bio-Rad protein assay).
For GST pull-down assay, cDNAs encoding dystrophin (amino acids
3194-3685),
-dystrobrevin (amino acids 422-564), and
-dystrobrevin (amino acids 444-606) were cloned in frame with GST
into the pGEX-2TK vector and introduced into E. coli JM109
cells. Twenty-ml overnight cultures were diluted 1:10 with LB medium
supplemented with 1 mM 2-mercaptoethanol and 20 mM glucose. After induction with 0.1 mM
isopropyl-
-D-thiogalactopyranoside, cells were washed in
PBS and resuspended in a 0.02 initial volume with 50 mM
glucose, 25 mM Tris-HCl (pH 8.0), 10 mM EDTA,
and 10 mg/ml lysozyme. After incubation for 10 min at room temperature
(all following steps were carried out at 4 °C or on ice), an equal
volume of 2× lysis buffer (final concentration: 50 mM
Tris-HCl (pH 8.0), 200 mM NaCl, 1 mM EDTA, 1%
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and
protease inhibitors) was added, and cells were fractured with repeated
cycles of freezing-thawing. The protein extract was clarified by
centrifugation at 20,000 × g for 30 min and incubated
with 100 µl of a 50% slurry of glutathione-agarose CL-4B (Fluka) for 2 h with shaking. After extensive washing in PBS supplemented with
1 mM phenylmethylsulfonyl fluoride and protease inhibitors, GST-dystrophin/dystrobrevin bead-bound fusion proteins was utilized in assay.
Antibody Production--
Anti-
1- and anti-
2-syntrophin
antibodies were generated by subcutaneous injection of New Zealand
White rabbits with 100 µg of purified
1-syntrophin-(195-302) and
2-syntrophin-(209-299) peptides, respectively, using the
immunization protocol previously described (18). The antiserum titer
(1:60,000 and 1:80,000, respectively) was determined by
enzyme-linked immunosorbent assay, and specificity was verified by
Western blotting.
Both antisera were affinity-purified on polyvinylidene difluoride
membrane (Roche Molecular Biochemicals) blocked with purified GST-
1-syntrophin-(195-302) and GST-
2-syntrophin-(209-299)
fusion proteins, respectively. Cyclic incubations of antiserum were
followed by elution of affinity-purified antibodies with 100 mM glycine (pH 2.7), neutralized with Tris base at a final
concentration of 25 mM at pH 7.8. For anti-
1-syntrophin
antiserum, a very weak cross-reactivity with
1-syntrophin was
eliminated by preincubation on polyvinylidene difluoride membrane
blocked with purified GST-
1-syntrophin-(173-505) fusion protein.
Affinity-purified antibodies were concentrated using an Ultrafree-CL
unit (Mr cutoff = 100,000; Millipore
Corp.), supplemented with 3% bovine serum albumin and 0.5%
NaN3, and stored at 4 °C.
Western Blotting--
Samples were run on 9% SDS-polyacrylamide
gel and transferred to nitrocellulose sheets. Membranes were incubated
for 2 h at room temperature with affinity-purified rabbit
polyclonal antibodies diluted 1:1000 in Tris-buffered saline (50 mM Tris-HCl (pH 8.0) and 200 mM NaCl) with
0.5% nonfat milk, 0.05% Tween 20, and 0.05% Nonidet P-40. After
washing, membranes were incubated for 1 h with
peroxidase-conjugated anti-rabbit IgG diluted 1:10,000 in Tris-buffered
saline with 0.5% nonfat milk, 0.05% Tween 20, and 0.05% Nonidet
P-40. Immunoreactive bands were visualized by ECL according to the
specifications of the manufacturer (Amersham Pharmacia Biotech).
Two-hybrid System for Protein-Protein Interaction--
The C
terminus of dystrophin (amino acids 3194-3685) and regions of
-dystrobrevin (amino acids 422-564) and
-dystrobrevin (amino
acids 444-606) were cloned in frame with the DNA-binding domain of
GAL4 into the pGBT9 plasmid (pGBT9-DYS, pGBT9-DTNA, and pGBT9-DTNB,
respectively), whereas
1-syntrophin (amino acids 19-517) and
2-syntrophin (amino acids 1-539) were cloned in frame with the
activating domain of GAL4 into the pGAD424 plasmid (pGAD-G1SYN and
pGAD-G2SYN, respectively) (CLONTECH). For
1-syntrophin, a plasmid in which exon 18 is deleted
(pGAD-G1SYN
18) was also utilized. In addition, human
1-syntrophin
(amino acids 173-505; pGAD-A1SYN) was utilized as a positive control
for the interaction with dystrophin and related proteins. The p53 and
pSV40 control plasmids were supplied with a kit.
The pGBT9-DYS, pGBT9-DTNA, and pGBT9-DTNB plasmids were cotransformed
in the YRG-2 yeast strain, containing two Gal4-inducible reporter
genes, HIS3 and lacZ, with pGAD-G1SYN,
pGAD-G1SYN
18, pGAD-G2SYN, or pGAD-A1SYN according to the
specifications of the manufacturer (CLONTECH). The
double transformants were plated onto selective plates lacking
tryptophan, leucine, and histidine to show the activation of the
Gal4-inducible HIS3 reporter gene through protein-protein
interaction. Positive clones were also replica-plated on selective
medium and tested for
-galactosidase activity using the colony lift
assay following the directions supplied with the kit obtained from
CLONTECH to confirm the interaction through the
activation of the second Gal4-inducible reporter gene, lacZ.
GST Pull-down Assay--
Full-length
1- and
2-syntrophins
were cloned into the pCT expression vector under the cytomegalovirus
promoter and transiently transfected into COS-7 cells by
electroporation. After 48-72 h, the cells were washed in PBS,
resuspended in lysis buffer (50 mM Tris-HCl (pH 8.0), 200 mM NaCl, 5 mM dithiothreitol, 1 mM
EDTA, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride,
and protease inhibitors), and incubated for 30 min at 4 °C with
shaking. The protein extract was clarified by centrifugation at
20,000 × g for 30 min at 4 °C. Then, 100 µl of
extract was incubated with 25 µl of GST-dystrophin/dystrobrevin
bead-bound fusion proteins and GST-alone bead-bound fusion protein
overnight at 4 °C with shaking. After extensive washing with buffer
containing 50 mM Tris-HCl (pH 8.0), 100 mM
NaCl, 1 mM dithiothreitol, 0.1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitors, 25 µl of sample buffer (125 mM Tris-HCl (pH 6.8), 8 M urea, 4% SDS, 100 mM dithiothreitol, and
0.001% bromphenol blue) was added to the beads. After boiling, samples
were run on 9% SDS-polyacrylamide gel and analyzed by Western blotting.
Rat Tissues--
Adult Wistar rats (3 months old, 250-300 g)
were killed under deep anesthesia (0.1 mg/g sodium barbital), and their
brains and spinal cords were quickly dissected out and frozen
immediately on dry ice. Cryostat sections 10 µm thick were collected
onto Superfrost Plus slides (Erie Scientific, Portsmouth, NH) and
stored at
80 °C until processed.
Riboprobe Preparation--
The rat
1- and
2-syntrophin
cDNA fragments obtained by RT-PCR were subcloned into the
EcoRV site of the pBluescript SK vector. The 701- and
432-nucleotide cRNA probes were transcribed in both the antisense and
sense orientations from the properly linearized plasmids, using 20 units of T3 or T7 RNA polymerase (Promega), 30 µM
35S-UTP (1300 Ci/mmol), and 10 mM each
unlabeled ATP, CTP, and GTP.
In Situ Hybridization--
In situ hybridization was
performed on 10-µm tissue sections from fresh frozen, non-perfused
rat brain and spinal cord as described (51, 52) with minor
modifications. Briefly, after fixation in 4% paraformaldehyde,
sections were treated with 0.5% acetic anhydride in 100 mM
triethanolamine (pH 8.0) and prehybridized for 1 h at 55 °C in
prehybridization buffer (50% formamide, 750 mM NaCl, 50 mM sodium phosphate buffer (pH 7.0), 10 mM
EDTA, 200 µg/ml heparin, 5× Denhardt's solution, and 0.5 mg/ml
purified tRNA) containing 10% dextran sulfate and 35S-RNA
probe (2 × 108 cpm/ml). After hybridization, sections
were treated with 20 µg/ml RNase, washed at high stringency for
1 h at 60 °C, and agitated overnight in 1× SSC. The dehydrated
sections were coated with NBT-2 emulsion (Eastman Kodak Co.) and
exposed for 2-5 weeks. The autoradiograms were developed, lightly
counterstained with methylene blue or hematoxylin and eosin, and
examined by dark- and bright-field microscopy. A sense strand probe
labeled to the equivalent specific radioactivity of the antisense probe
was used on adjacent sections in all experiments to check for
background hybridization.
Immunohistochemistry--
Sections were dried at room
temperature, fixed in cold acetone, and pretreated with 0.3%
H2O2 in PBS to quench the endogenous peroxidase
activity; rinsed in PBS; and incubated with 10% normal goat serum and
0.2% Triton X-100 for 60 min to mask nonspecific adsorption sites.
Sections were then incubated for 1 h at room temperature with the
anti-
1- and anti-
2-syntrophin rabbit polyclonal antibodies
(diluted 1:200 in PBS). Omission of the primary antibodies or their
replacement by preimmune sera was used for control experiments. After
several rinses in PBS, the sections were incubated with biotinylated
goat anti-rabbit IgG, washed in PBS, and then incubated with the ABC
complex according to the manufacturer's instructions (Vectastain ABC,
Vector Labs, Inc.). Peroxidase staining was obtained by incubating the
sections in 0.075% 3,3'-diaminobenzidine and 0.002%
H2O2 in 50 mM Tris buffer (pH 7.6)
for 10 min. In control experiments, when primary antibodies were
omitted or replaced by nonimmune sera, the immunoreaction did not take place.
Immunofluorescence of Human Muscle--
Unfixed cryostat
sections (5 µm thick) were cut from diagnostic muscle biopsies,
air-dried, fixed in cold acetone, preincubated with 10% normal goat
serum in PBS for 30 min, and incubated for 1 h at room temperature
with a 1:50 dilution of anti-
1- or anti-
2-syntrophin antibody in
PBS containing 1% bovine serum albumin. After several rinses in PBS,
indirect immunofluorescence was visualized using biotinylated secondary
antibodies (1:40) and fluorescein isothiocyanate-labeled streptavidin
(1:250) (Amersham Pharmacia Biotech). Sections were covered with
a glycerol mount and examined with an Olympus photomicroscope equipped with epifluorescence.
 |
RESULTS |
Isolation and Sequence Analysis of Syntrophin cDNAs--
The
peptide sequences of human and mouse
1-syntrophin
(GenBankTM/EBI Data Bank accession numbers U40571 and
U00677, respectively),
1-syntrophin (L31529 and U89997,
respectively), and
2-syntrophin (U40572 and U00678, respectively)
were matched using the TBLASTn algorithm with electronic data base
sequences, including the subset of ESTs. Two distinct EST groups were
retrieved. Each belong to novel cDNAs, having significant amino
acid similarity to the three human syntrophins. The former sequence was
found in human ESTs H16675, R13432, and R25045, and the latter in human
EST Z43606. Clones 49263 and c-1gb01, for the first and second
sequences, respectively, derived from an infant brain cDNA library,
provided by IMAGE Consortium. These clones were sequenced and used as
probes for further screening of human fetal brain and NT2 neuronal
precursor cell cDNA libraries. Altogether, 16 clones (eight for
each probe) were isolated to confirm and complete the sequence of both cDNAs.
The former cDNA, initially named syn4, is 1898 bp long
and includes an open reading frame of 1554 nucleotides
(GenBankTM/EBI accession number AJ003030). It encodes a
protein of 517 amino acids with a predicted molecular mass of 57,932 Da
and a calculated isoelectric point of 6.24. The latter cDNA,
initially named syn5, is 1938 bp long and contains an open
reading frame of 1620 nucleotides (GenBankTM/EBI accession
number AJ003029). It encodes a protein of 539 amino acids with a
predicted molecular mass of 60,066 Da and a calculated isoelectric
point of 7.59. Some differences have been observed for a few
syn4 and syn5 clones. These are likely due to
alternative splicing. For both cDNAs, the sequence flanking the
first ATG is in accordance with the Kozak consensus for translational start sites (53). In agreement with other investigators, we have
renamed syn4 and syn5 as
1-syntrophin and
2-syntrophin, respectively.
Peptide similarity (40-44%) to the human syntrophins spanned
the entire open reading frames. Similarity to a Caenorhabditis elegans protein (U49829) is higher (46-52%). The
1- and
2-syntrophins share a 73% amino acid similarity, thus suggesting
that the two proteins are much more closely related and probably
derived from a common single syntrophin precursor.
Computational Analysis of Protein Sequence--
The syntrophin
sequences share distinctive conserved motifs: two PH domains and one
PDZ domain, with the first PH domain split into two regions (PH1a and
PH1b) by the PDZ domain and its flanking regions (32, 33). In addition,
another region has been recognized in the C-terminal 57 amino acids and
termed the SU domain (32, 33). There are indications that this domain
is involved in dystrophin binding.
We have produced a multiple sequence alignment of all syntrophins using
the CLUSTAL W1.7 program (49) (Fig. 1).
The
1- and
2-syntrophins are very similar to the other
syntrophins in the PDZ domain. The PH domain is not easy to recognize
since it includes a series of relatively poorly conserved peptides
interspersed with less conserved linker sequences. These may vary from
a few amino acids to 100 or more, often containing other functional domains. Nevertheless, the C-terminal 15 or so amino acids contain only
an invariant Trp residue, and the six N-terminal residues from this
amino acid frequently include two or more negatively charged residues
as well as glutamic acid (46). The alignment shows that both the
C-terminal Trp residues of the PH1 and PH2 domains are present in
1-
and
2-syntrophins (Fig. 1), suggesting that both domains can be
conserved.

View larger version (96K):
[in this window]
[in a new window]
|
Fig. 1.
Multiple sequence alignment of the
known syntrophins. The alignment includes mouse
(MOU-A1SYN; U00677), rabbit (RAB-A1SYN; U01243),
and human (HUM-A1SYN; U40571) 1-syntrophin; mouse
(MOU-B1SYN; U89997) and human (HUM-B1SYN; I59291)
1-syntrophin; mouse (MOU-B2SYN; U00678) and human
(HUM-B2SYN; U40572) 2-syntrophin; and human
1-syntrophin (HUM-G1SYN) and 2-syntrophin
(HUM-G2SYN). We have also considered the T. californica syntrophin (TCA-SYN; U00676) and two
proteins of C. elegans similar to syntrophins
(CEL-SYN1, Z81072; and CEL-SYN2, U49829). The
PDZ, PH, and SU domains are boxed. The arrows
indicate the putative conserved Trp residue at the C terminus of PH
domains.
|
|
The SU domain is less homologous, with only a weak similarity to the
other three syntrophins. The proposed secondary structure of the SU
domain is composed of three to five
-sheets separated by as many
turns (33). Using the PHDsec algorithm (50), the predicted secondary
structure of
1- and
2-syntrophins is mainly arranged into an
-helix.
We analyzed
1- and
2-syntrophins using the PROFILESCAN program. A
PDZ domain was identified in both proteins (residues 57-140 for
1-syntrophin and residues 73-156 for
2-syntrophin) and only one
PH domain, corresponding to the PH2 domain of the other syntrophins (residues 283-390 for
1-syntrophin and residues 296-421 for
2-syntrophin) (Fig. 1). No other domain was found. In addition, we
have also identified, in both proteins, an ATP/GTP-binding site
motif A (P-loop) (54) (residues 440-448 for
1-syntrophin and
residues 471-479 for
2-syntrophin). This motif is a glycine-rich
region that typically forms a loop between a
-strand and an
-helix. This loop interacts with one of the phosphate groups of the
nucleotide. Many potential phosphorylation sites have also been
identified with no clear relationship to the other syntrophins.
Phylogenetic analysis of all syntrophins establishes a common origin of
the syntrophins with a early separation into two groups: the first
including
1-,
1-, and
2-syntrophins, and the second including
1- and
2-syntrophins. The two C. elegans syntrophins are final confirmation.
Tissue Distribution of
1- and
2-Syntrophin
Expression--
The expression of
1- and
2-syntrophins in human
and rat adult tissues was assayed by Northern blotting, using fragments of the respective cDNAs as probes.
Expression of
1-Syntrophin Is Brain-specific in Humans and
Rats--
In man, only an ~7.0-kb transcript was observed using a
426-bp cDNA probe encoding the last 126 amino acids (Fig.
2a). Conversely, the rat
cDNA probe (701 bp), corresponding to amino acids 29-290 of human
1-syntrophin, hybridized with three equally abundant transcripts of
~2.6, 3.4, and 7.5 kb (Fig. 2b). The different probes may
reflect the different expression pattern. The mRNAs are much longer
than the coding sequence, and a long 3'-UTR and/or 5'-UTR is probably
present. The expression of further
1-syntrophin isoforms most likely
originates by alternative splicing. For example, exon 18 is in-frame
spliced out in clone 49263, and so is the fourth exon in another
1-syntrophin cDNA clone. Other alternatively spliced products
were identified by RT-PCR (data not shown).

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 2.
Distribution of mRNA for
1- and 2-syntrophins in
human and rat tissues. In a, a human multiple tissue
Northern blot (CLONTECH) was hybridized with a
426-bp cDNA fragment encoding the last 126 amino acids of human
1-syntrophin. The tissues represented in each lane are as follows:
lane 1, heart; lane 2, brain; lane 3,
placenta; lane 4, lung; lane 5, liver; lane
6, skeletal muscle; lane 7, kidney; lane 8,
pancreas. In b and c, a rat multiple tissue
Northern blot (Origene) was hybridized with an amplified 702-bp
cDNA fragment of rat 1-syntrophin (b), corresponding
to the region encoding amino acids 58-290 of human 1-syntrophin,
and an amplified 432-bp cDNA fragment of rat 2-syntrophin
(c) that encodes amino acids 93-236 of human
2-syntrophin. The tissues represented in each lane are as follows:
lane 1, brain; lane 2, heart; lane 3,
kidney; lane 4, lung; lane 5, testis; lane
6, skin.
|
|
Conversely,
2-syntrophin has a broader but weaker expression. A
clearer picture of
2-syntrophin comes from rat Northern blots (Fig.
2c). In addition to brain with two transcripts of ~2.1 and
2.3 kb and a third very weakly hybridizing transcript of 2.5 kb, a
mRNA of 2.1 kb was also observed in testis. Weak signals at 0.8, 2.2, and 2.5 kb were also present in kidney and lung, as well as a
weaker 1.6-kb transcript in heart.
These different transcripts are probably related to isoforms of this
gene. Evidence for this hypothesis comes from cDNA library screening and RT-PCR of human brain cDNA. In particular, we have characterized two isoforms. In the first, exons 3-5, corresponding to
the first half of the PDZ domain, are in-frame spliced out; and in exon
9, a putative 5'-donor splicing site at bp 693 leads to in-frame
deletion of the last 27 bp of this exon, corresponding to amino acids
830-839. Interestingly, the consensus of the protein kinase C
phosphorylation site can be recognized in this fragment. In the second
isoform, exons 3-6 are equally in-frame spliced out, and the PDZ
domain is nearly entirely eliminated.
Genomic Structure and Chromosomal Mapping--
Genomic library
screening and long-range and vectorette PCR were used to determine
exon-intron boundaries of these genes. The
1-syntrophin gene
(SNTG1) has 19 exons (Table
I). The first two exons contain the
5'-UTR, and the first methionine is in the third exon. The
2-syntrophin gene (SNTG2) has at least 17 exons (Table
II). The first exon includes the first
methionine. For both genes, the termination signal in the last exon is
followed by a 3'-UTR colinear with the genomic sequence. The exon
structure and splicing sites are conserved in the coding sequences
between
1- and
2-syntrophins (Tables I and II), suggesting a
common origin.
View this table:
[in this window]
[in a new window]
|
Table I
Genomic organization of 1-syntrophin
For each exon, the sequence at exon-intron boundaries is shown,
as well as the length and the corresponding region or domain. The
numbers 0, 1, and 2 indicate the splicing phase when the interruption
falls before the first, second, or third base of a codon.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Genomic organization of 2-syntrophin
For each exon, the sequence at exon-intron boundaries is shown, as well
as the length and the corresponding region or domain. The numbers 0, 1, and 2 indicate the splicing phase when the interruption falls before
the first, second, or third base of a codon.
|
|
Two methods were employed for chromosomal mapping. For
1-syntrophin, PCR primers, designed from genomic sequences
around exons 1 and 19, were used to screen a yeast artificial
chromosome library and a radiation hybrid panel (Genebridge 4, Research
Genetics). One yeast artificial chromosome clone (856d11) containing
the markers AFMB353XD9, D8S589, and D8S1652 (chromosome 8q11) was identified. Radiation hybrid mapping confirmed the chromosomal location
at 8q11 between D8S1622 and AFMB353XD9 (4.7 centirays from AFMB353XD9).
2-Syntrophin was mapped to chromosome 2 at p25 between D2S323 and
D2S330 (1.7 centirays from D2S323) by radiation hybrid using PCR
primers flanking exon 12.
In Vivo and in Vitro Assays of Binding with Dystrophin--
The
1-,
1-, and
2-syntrophins have been shown to bind dystrophin,
utrophin, and dystrobrevins in vitro (34, 35, 39, 40, 55).
To verify whether
1- and
2-syntrophins can also bind dystrophin
or related proteins, assays of protein-protein interaction were used.
In addition, we performed a GST pull-down assay. The C terminus of
dystrophin or
- or
-dystrobrevin was fused to glutathione
S-transferase protein in the pGEX-2TK plasmid, expressed in
E. coli cells, and purified on glutathione-agarose beads.
The full-length coding sequences of
1- and
2-syntrophins were
then cloned, as sense and antisense, into the pCT plasmid and
transfected into COS-7 cells. The protein extracts were incubated with
the bead-bound fusion proteins and, after extensive washing, analyzed
by Western blotting.
To detect
1- and
2-syntrophins, we used immunopurified rabbit
antibodies raised against GST-
1-syntrophin-(195-302) and GST-
2-syntrophin-(209-299) fusion proteins. The
1- and
2-syntrophins were affinity-purified by the
GST-dystrophin/dystrobrevin bead-bound fusion proteins, and no signals
were observed in control lanes (Fig.
3).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
In vitro assay of interaction with
dystrophin and related proteins by GST pull-down assay. In both
Western blots (to the left), the specificity of affinity-purified
polyclonal antibody was tested on a panel of GST fusion proteins. COS-7
protein extracts in which the expression of 1-syntrophin
(a) or 2-syntrophin (b) had been induced were
incubated with GST bead-bound fusion proteins: GST alone (lane
A), GST-DYS (lane B), GST-DTNA (lane C), and
GST-DTNB (lane D).
|
|
The two-hybrid system is a yeast-based genetic assay to detect in
vivo protein-protein interaction (56, 57). In the assay, one
protein is fused with the DNA-binding domain, and the other with the
transcription activation domain of GAL4. Should an interaction occur,
the resulting dimer induces reporter gene activation (HIS3 and lacZ). To confirm this interaction in vivo,
the dystrophin C terminus (residues 3194-3685) corresponding to exons
66-79 and regions of
-dystrobrevin (residues 422-564) and
-dystrobrevin (residues 444-606), all with the syntrophin-binding
site, were fused to the DNA-binding domain of GAL4 in the pGBT9 plasmid
(pGBT9-DYS, pGBT9-DTNA, and pGBT9-DTNB, respectively), whereas
1-syntrophin (residues 19-517) and
2-syntrophin (residues
1-539) were fused to the activating domain of GAL4 in the pGAD plasmid
(pGAD-G1SYN and pGAD-G2SYN, respectively). In addition, human
1-syntrophin (residues 173-505), fused to the activating domain of
GAL4 in the pGAD plasmid (pGAD-A1SYN), was used as a positive control of interaction with dystrophin and related proteins. The pGBT9-DYS, pGBT9-DTNA, and pGBT9-DTNB plasmids were cotransformed in yeast strain
YRG-2 with pGAD-G1SYN, pGAD-G2SYN, and pGAD-A1SYN on selective Leu
and Trp
plates and then streaked on
His
plates to test the activation of the HIS3
reporter gene.
The
1- and
2-syntrophins interacted with dystrophin in
vivo (Fig. 4, a and
b). For
1-syntrophin, we also used an isoform without
exon 18 (pGAD-G1SYN
18) that includes the ATP/GTP-binding site. This
isoform did not interact with dystrophin, confirming that the
dystrophin-binding site is located at the C terminus, presumptively in
the last 80 amino acids.
-Dystrobrevin interacted with
2-syntrophin, but only weakly with
1-syntrophin (Fig.
4c). Conversely, both syntrophins bound to
-dystrobrevin
(Fig. 4d). These findings were confirmed by testing for
-galactosidase activity (data not shown).

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 4.
In vivo assay of interaction with
dystrophin and related proteins using the yeast two-hybrid system.
The 1- and 2-syntrophins were tested with dystrophin
(a and b) and with - and -dystrobrevins,
respectively (c and d). In the table,
the cotransformed plasmid pairs are indicated for each sector of
plates. Dys, dystrophin; DtnA, -dystrobrevin;
DtnB, -dystrobrevin; Syn, syntrophin.
|
|
In Situ Hybridization in Rat Central Nervous System
Tissues--
1- and
2-syntrophin mRNAs were detected by
in situ hybridization in all rat central nervous system
regions examined; and in particular, they were highly expressed by
neuronal cells. The expression of syntrophin transcripts was mainly
restricted to cells with neuronal morphology. Hybridization grains for
the
1- and
2-syntrophin mRNAs were localized in the
perikaryon and proximal portion of the neuronal processes. Strong
hybridization signals were localized in the hippocampus, neuron-rich
dentate granule cells, and pyramidal cell layers (Fig.
5). Intense labeling was observed in
neurons of the cerebral (parietal and frontal) cortex (Fig.
5G).
1- and
2-syntrophin mRNAs were also expressed
in the cerebellar cortex, deep cerebellar nuclei, thalamus, and basal ganglia (data not shown). A very strong mRNA signal was present within neurons of both anterior and posterior horns of the spinal cord,
whereas a lower signal could be detected in the white matter (Fig. 5,
C and E). No specific signal over the background
was detectable after hybridization of adjacent sections with the sense strand probe (data not shown). This confirmed the specificity of
hybridization. Moreover, RNA studies were concordant with the distribution of the
1- and
2-syntrophin immunoreactivities. Using
polyclonal antibodies raised against
1- and
2-syntrophins, we
observed reactivities in the same cell populations containing abundant
levels of the corresponding mRNAs (Fig. 5, B,
D, F, and H), thus confirming that
1- and
2-syntrophin gene products are indeed highly expressed in
the central nervous system. The widespread, albeit uneven, distribution
of
1- and
2-syntrophin transcripts and proteins throughout
different cerebral and spinal areas suggests that
1- and
2-syntrophin genes play an important housekeeping role in
neurons.

View larger version (157K):
[in this window]
[in a new window]
|
Fig. 5.
In situ hybridization and
immunohistochemistry of rat central nervous system tissues. Shown
are dark-field photomicrographs of in situ hybridization
analysis of 1-syntrophin (A and C) and
2-syntrophin (E and G) mRNAs compared with
1-syntrophin (B and D) and 2-syntrophin
(F and H) immunohistochemistry detected in
representative fields of close (not adjacent) tissue sections.
A, coronal section of rat hippocampus showing strong signals
in neuron-rich dentate granule cells and pyramidal cell layers;
B, 1-syntrophin immunoreactivity distribution in the
hippocampus; C, 1- and 2-syntrophin mRNAs
abundantly expressed in neurons of both ventral and dorsal horns of rat
cervical spinal cord (a positive signal is present in the white matter
overprojection emerging from the gray matter); D, intense
labeling with 1-syntrophin antibody observed over neuron perykarya
and in cross-sectioned axons or dendrites; E,
2-syntrophin transcript diffusely expressed in the gray matter of
the spinal cord, showing the highest hybridization signal in the
ventral horn; F, 2-syntrophin-immunopositive neurons in
the ventral horn; G, intense signal for 2-syntrophin
mRNA detected in rat cerebral neocortex, particularly in the
infragranular layers; H, pyramidal and multipolar neurons of
the frontal cortex intensely labeled with anti- 2-syntrophin
antibody. Original magnification: ×25 in A and
B; ×40 in C, D, G, and
H; and ×200 in E and F.
|
|
Immunofluorescence of Human Muscle--
No signal was found with
anti-
1-syntrophin antibody (Fig.
6A).
2-Syntrophin showed a
strong sarcolemmal immunoreactivity in all muscle fibers (Fig.
6B). In DMD patients with absence of dystrophin,
2-syntrophin was absent or severely reduced (Fig. 6C); In
contrast, a normal plasmalemmal signal was observed in patients with
neurogenic atrophy (Fig. 6D). Upon immunofluorescence,
2-syntrophin was not selectively localized at the neuromuscular junctions and was present on the membrane of cardiomyocytes in two
biopsy specimens (data not shown).

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 6.
Immunofluorescence of human muscle.
Shown is the 1-syntrophin (A) and 2-syntrophin
(B-D) immunofluorescence of normal muscle (A and
B) and of muscle from patients with DMD (C) and
neurogenic atrophy (D). Original magnification: ×400 in
A and D; and ×200 in B and
C.
|
|
 |
DISCUSSION |
Originally identified in postsynaptic membranes of T. californica (29), syntrophins are intracellular peripheral
membrane proteins of ~58 kDa that, in man and mouse, exist in three
highly conserved but distinct isoforms (
1,
1, and
2) encoded
by different genes (30, 31, 33). The name "syntrophin" was
introduced to indicate that this group of proteins accompanies
dystrophin. Further studies have demonstrated that syntrophins also
accompany all the other proteins of the dystrophin family such as
utrophin (dystrophin-related protein 1) (35), dystrophin-related
protein 2, and dystrobrevins (
and
) (37, 38). Binding is
mediated by amino acid sequences that are homologous to the
cysteine-rich domain and C-terminal region of dystrophin encoded by
exon 74 (34, 39, 40).
The role of syntrophins and their requirement for muscle and nerve cell
function are still obscure. To date, no human disease has been
associated with a syntrophin gene mutation. Likewise, no gross
histological changes in the skeletal muscle of
1-syntrophin knockout
mouse (the first syntrophin-deficient animal model) have been reported
(58). This may be due to a redundancy of the genes of the syntrophin
family. The lack of function of one gene could be replaced by other
members of the family, coexpressed in the same tissues. In man, the
1-syntrophin transcript is predominantly expressed in skeletal and
cardiac muscle, whereas the
1- and
2-syntrophin transcripts are
expressed in a wide variety of tissues (31, 33, 37). In addition,
histochemical studies with specific antibodies revealed that the three
syntrophins are all present at the neuromuscular junction.
1-Syntrophin is also found at the sarcolemma, whereas
1-syntrophin occurs at the sarcolemma of fast twitch muscle fibers
(37). We indicate here that the syntrophin gene family should include
at least two other members, which are less related to the primary
sequences of known syntrophins, but retain the property of dystrophin
binding.
1- and
2-syntrophins should be considered a separate
entity because of their relatedness (73% similarity), the common
C. elegans ancestor gene, and the genomic organization. In
particular, these two genes are split into 17-19 exons by long introns
at corresponding positions that are different from the exon-intron
boundaries found in the other syntrophins. In addition, we observed a
complex pattern of alternatively spliced products, with the presence,
at least for
2-syntrophin, of both translated and nonfunctional transcripts.
Expression data indicate that
1-syntrophin is restricted to neurons.
2-Syntrophin has a broader expression and a more complex pattern of
splicing and is presumably included in the dystrophin-associated complex beneath the muscle membrane at the sarcolemma. In fact, some
DMD patients show a secondary reduction of
2-syntrophin protein expression.
The ability of
1- and
2-syntrophins to bind dystrophin and
dystrobrevins (
and
) has been confirmed in vivo and
in vitro. Binding is mediated by the last 80 amino acids, a
region with weak similarity to the SU domain, the putative
dystrophin-binding site. The homologous cysteine-rich domain and
C-terminal region of dystrophin and related proteins include the
syntrophin-binding site and several potential binding domains (59, 60).
In particular, a coiled-coil motif, flanking the syntrophin-binding
site, links dystrophin to the same motif in the C terminus of
dystrobrevin. Therefore, dystrophin interacts with
dystrophin-glycoprotein complexes via the cysteine-rich domain and
heterodimerizes with dystrobrevins via the coiled-coil motif (61).
Together, dystrophin and dystrobrevin can recruit two syntrophins. This
model seems to be confirmed by the observation that dystrophin
complexes are highly enriched in
1- and
1-syntrophins, whereas
utrophin complexes contain mostly
1- and
2-syntrophins (37).
Different pairings are possible between the syntrophins:
1- and
2-syntrophins increase the possible combinations in brain.
DMD and Becker muscular dystrophy patients with point mutations or
deletions localized in the 3'-region of the dystrophin gene in addition
to the progressive muscle wasting show a higher incidence of mental
retardation, with learning disorders and speech difficulties (62). In
contrast, mutations localized in other parts of the gene are usually
not associated with mental retardation. There is no explanation for
this clinical observation because dystrophin is absent or severely
reduced in DMD patients, regardless of where the primary nonsense
mutation occurs. The presence of additional promoters located in
certain dystrophin gene introns could still generate functional
mini-dystrophin 3'-transcripts (apodystrophins), unless the mutation
does not directly involve the 3'-exons. The latter part of the
dystrophin gene encodes the region endowed with the
dystroglycan-binding site (exon 65) and the syntrophin-binding site
(exons 73-74).
In the brain,
1- and
2-syntrophins as well as
-dystrobrevin
can bind dystrophin isoforms Dp71 and Dp140 (63). In common with
dystrophin and
-dystrobrevin,
1- and
2-syntrophins are found
in the cortex and hippocampal formation. These data provide evidence
that the composition of the dystrophin-associated protein complex in
the brain differs from that in muscle (64). A mouse transgene
overexpressing apodystrophin-1/Dp71 (exons 63-79) in dystrophin-deficient animals (mdx mice) could not restore
the normal muscle phenotype (65, 66). This suggests that this dystrophin fragment alone has no influence on the muscle disease progression. It is possible that the presence of an intact C-terminal fragment could be important for the associated mental disorders. The apodystrophin-dystroglycan complex in the central nervous system
can bind the
1- and
2-syntrophins. Further studies are needed to
determine the role of these novel syntrophins in neuron signaling
processes and whether their concomitant lack affects learning.